Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elanco Animal Health filings document the disclosures of a public animal health company focused on products for farm animals and pets. The record includes Form 8-K reports on operating results, clinical or regulatory matters, capital-structure updates, credit-facility amendments, investor presentations, and restructuring-related exit or disposal activities.
Elanco's proxy materials describe board composition, shareholder voting matters, executive compensation, equity awards, and governance practices. Its filings also provide formal disclosure around material events, financial reporting, and the capital arrangements that support the company's global animal health operations.
Modi Rajeev A. reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health executive Rajeev A. Modi received a grant of 61.5901 deferred stock units tied to common stock. These units are part of an Executive Deferral and Stock Match Plan and will settle in cash or shares after employment ends or in a specified future year. Following this award, Modi holds 9,072.9178 deferred stock units.
VanHimbergen Robert M reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen received a grant of 8.216 deferred stock units, each linked to one share of Elanco common stock or its cash equivalent. Following this grant, his reported deferred stock unit balance is 48.7929 units. These units will settle in cash or stock after his employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan, so this filing reflects compensation rather than an open‑market trade.
Modi Rajeev A. reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health executive Rajeev A. Modi received a grant of 1,360.2363 deferred stock units on Company common stock as compensation. The grant was valued at $23.36 per unit and increased his directly held deferred stock units to 9,011.3277.
Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent. These units will settle in cash or shares after termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan, making this a routine, non‑market award rather than an open‑market purchase.
Simmons Jeffrey N reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc President and CEO Jeffrey N. Simmons received a grant of 4,497.6194 deferred stock units linked to the company’s common stock. Each unit represents the right to receive one share of common stock or the cash equivalent in the future, typically after employment ends or in a specified year. Following this award, his reported deferred stock unit balance is 23,677.3833 units, reflecting compensation rather than an open-market stock purchase or sale.
Elanco Animal Health executive vice president and CFO Robert M. VanHimbergen reported a compensation-related grant of deferred stock units. He acquired 9.485 deferred stock units tied to Company common stock, bringing his direct holding in this award type to 40.5769 units. Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent, settling in cash or shares after employment ends or in a specified future year under the Executive Deferral and Stock Match Plan.
Correia de Simas Jose Manuel reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health officer Correia de Simas Jose Manuel received a grant of 17,637.8425 deferred stock units on Company common stock at a reference value of $23.36 per unit. Following this award, he holds 22,280.4709 deferred stock units. These units will be settled in cash or shares after employment ends or in a designated future year under the Executive Deferral and Stock Match Plan.
Elanco Animal Health Inc officer Rajeev A. Modi reported a tax-related share disposition. On 2026-03-03, he disposed of 4,392 shares of common stock through a tax-withholding disposition at $24.88 per share, leaving 155,901 shares held with direct ownership after the transaction.
Elanco Animal Health Inc general counsel and corporate secretary Shiv O'Neill reported a Form 4 transaction involving company common stock. On March 3, 2026, O'Neill had 4,738 shares disposed of in a tax-withholding disposition at $24.88 per share, leaving 83,834 shares of directly owned common stock reported after the transaction. This disposition reflects shares withheld to cover tax obligations rather than an open-market sale.
Elanco Animal Health Inc President, CEO and Director Jeffrey N. Simmons reported a tax-withholding disposition of 37,898 shares of common stock on March 3, 2026. The disposition, coded as a payment of tax liability, was priced at $24.88 per share.
After this transaction, Simmons directly held 2,051,898 shares of Elanco common stock. A separate line shows an indirect holding of 167,000 shares held by a revocable trust, reported as indirect beneficial ownership.
Elanco Animal Health Inc officer Timothy J. Bettington reported a tax-withholding disposition of 4,695 shares of common stock on March 3, 2026. The shares were transferred at $24.88 per share to cover tax obligations, rather than sold in an open-market transaction. After this transaction, Bettington directly held 143,261 shares of Elanco common stock.